CN Patent

CN112004525A — 注射用组合物

Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2020-11-27 · 5y expired

What this patent protects

本发明涉及来曲唑组合物，其适于形成包含聚乳酸(PLA)的可生物降解的无菌热塑性聚合物的原位肌内植入物，用于每天给予需要该组合物的患者0.1‑2mg来曲唑。

USPTO Abstract

本发明涉及来曲唑组合物，其适于形成包含聚乳酸(PLA)的可生物降解的无菌热塑性聚合物的原位肌内植入物，用于每天给予需要该组合物的患者0.1‑2mg来曲唑。

Drugs covered by this patent

Patent Metadata

Patent number
CN112004525A
Jurisdiction
CN
Classification
—
Expires
2020-11-27
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.